Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Only a minority consistently meet timely targets set out by the AHA and ACC. This is a “call to action,” Harold Dauerman says ...

Elevations in cardiac troponin (cTn) after long bouts of aerobic exercise are not associated with subclinical coronary artery ...

These data suggest that private equity-acquired hospitals are cherry-picking the healthiest patients as part of an effort to ...

Most cases are subclinical, but given the newness of the therapy, it’s necessary to keep tabs on the issue going forward.

Outcomes in the observational study were better among patients treated by surgeons who regularly do ablations.